Abstract Details

Title Real-world Assessment of Neurofilament Light Chain Levels in ALS and Other Neuronal Disorders

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P11 - Poster Session 11 (8:00 AM-9:00 AM)

Poster/Presentation
Number 11-023

Objective

We sought to outline patterns of serum NfL levels obtained via commercial lab testing in our Neurology department patient population, aiming to discern whether there were significant differences between a neurodegenerative disease, ALS, and other types of neuronal disorders.

Background Neurofilament light chain (NfL), a neuronal cytoplasmic protein, has emerged as a potential marker of axonal damage, offering insights into disease diagnosis and management (Gaetani et al., 2019). However, since serum NfL testing has become commercially available, its use in the clinical setting has not been extensively explored. An understanding of the use of commercial assays and its application to different neurological clinical settings may be valuable.

Design/Methods We examined all serum NfL test results ordered by Neuromuscular or Neuroimmunology providers for patients in our clinic through the same commercial laboratory (Labcorp). We assessed patients with four diagnoses, ALS, MS, autoimmune neuropathies, and other neuropathies, evaluating 16 test results in the ALS group, 81 in the MS group, 3 in the autoimmune neuropathies (GBS/CIDP) group, and 118 in the group with other neuropathies.

Results Mean serum NfL levels of patients differed significantly by diagnosis (ANOVA, F[3, 212] = 16.71; p < 0.001) and according to age (ANOVA, F[1, 212] = 56.96; p < 0.001). Including age as a covariate, the ALS group had greater mean NfL levels than MS (p < 0.001) and other neuropathies (p < 0.001), while the mean NfL levels of all other pairwise comparisons did not differ significantly (p > 0.1).

Conclusions

Our real-world data is consistent with data from clinical trials, indicating patterns of NfL levels in various disease states, with neurodegenerative disorders being associated with higher NfL levels than demyelinating diseases (Gaetani et al., 2019). Commercial serum NfL testing could be a valuable tool particularly for neurologists working with patients with neurodegenerative diseases.

Authors/Disclosures
Gabriella Law PRESENTER	Ms. Law has nothing to disclose.
Micah Hamilton	Mr. Hamilton has nothing to disclose.
Nicholas S. Streicher, MD	Dr. Streicher has nothing to disclose.
Shakti Nayar, MD	Dr. Nayar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Nayar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyverna. Dr. Nayar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ArgenX. Dr. Nayar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi.

��ɫ��

��ɫ��